Adverse effects of statins;Effets indésirables des statines

Therapie

Volumn 58, Issue 1, 2003, Pages 77-83

  Andréjak, Michel ^a,c   Gras, Valérie ^a   Massy, Ziad A ^a   Caron, Jacques ^b  

^a Service de Pharmacologie Clinique   (France)

^b CRPV de Lille   (France)

^c AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

Cancer; Cerivastatin; HMG CoA reductase inhibitors; Rhabdomyolysis; Statins

Indexed keywords

AMINOTRANSFERASE; CERIVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG MARKETING; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HUMAN; LIVER LEVEL; MYALGIA; MYOPATHY; OPHTHALMOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 0038075475     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie:2003011     Document Type: Review

References (40)

1. Pfeiffer MA, Keech A, Sacks FM, et al. Safety and tolerabilility of pravastatin in long-term clinical trials. Prospective Pravastatin Pooling (PPP) Project. Circulation 2002; 105: 2341-6
2. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22
3. Gaist D, Rodriguez LA, Huerta C, et al. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology 2001; 12: 565-9
4. Pasternak RC, Smith SC, Bairey-Merz CN, et al. AAC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002; 40: 567-72
5. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002; 12: 565-9
6. Ucar M, Mjörndal T, Dahlquist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 2000; 22: 441-57
7. Phillips PS, Haas RH, Bannykh S, et al. Statin-associated myopathy with normal creatine kinase levels. Arch Int Med 2002; 137: 581-5
8. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001; 35: 1095-107
9. Franc S, Bruckert E, Giral P, et al. Rhabdomyolyse chez des patients ayant une myopathie préexistante et traités par des agents hypolipémiants. Presse Med 1997; 26: 1855-8
10. Leung NM, Ooi TC. Use of statins and fibrates in hyperlipidemic patients with neuromuscular disorders. Ann Intren Med 2000; 132: 417-8
11. Watts GF, Castelluccio C, Rice-Evans C, et al. Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin. J Clin Pathol 1993; 46: 1055-7
12. Laaksonen R, Jokelainen K, Laakso J, et al. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and ubiquinone in skeletal muscle. Am J Cardiol 1996; 77: 851-7
13. Sinzinger H, Lupatteli G, Chehne F. Increased lipid peroxidation in a patient with CK elevation and muscle pain during statin therapy. Atherosclerosis 2000; 153: 255-6
14. Giordano N, Senesi M, Mattii G, et al. Polymyositis associated with simvastatin. Lancet 1997; 349: 1600-1
15. Schalke BB, Schmidt B, Toyka K, et al. Pravastatin-associated inflammatory myopathy. N Engl J Med 1992; 327: 649-50
16. England JD, Walsh JC, Stewart P, et al. Mitochondrial myopathy developing on treatment with the HMG-CoA reductase inhibitors-simvastatin and pravastatin. Aust NZ J Med 1995; 25: 374-5
17. Evans M, Rees A. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same? Drug Saf 2002; 25: 649-63
18. Morita I, Sato I, Ma L, et al. Enhancement of membrane fluidity in cholesterol-poor endothelial cells pre-treated with simvastatin. Endothelium 1997; 5: 107-13
19. Lijnen P, Celis H, Fagard R, et al. Influence of cholesterol lowering on plasma membrane lipids and cationic transport systems. J Hypertens 1994; 12: 59-64
20. Farmer JA. Learning from the cerivastatin experience. Lancet 2001; 358: 1383-5
21. Gadbut AP, Caruso AP, Gabler JB. Differencial sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin. J Mol Cell Cardiol 1995; 27: 1191-9
22. Masters BA, Palmoski MJ, Flint OP, et al. In vitro myotoxicity of the 3-hydroxy3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin and simvastatin, using neonatal rat skeletal myocytes. Toxicol Appl Pharmacol 1995; 131: 163-74
23. Becquemont L. Interactions médicamenteuses et hypolipémiants. Thérapie 2003; 58: 85-90
24. Davidson MH, Stein EA, Dujovne CA, et al. The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol 1997; 257: 38-42
25. Feely WD. Pharmacokinetic-pharmacodynamic drug interactions with HMGCoA reductase inhibitors. Clin Pharmacokinet 2002; 41: 343-70
26. Afssaps. Risque musculairedes statines. Available from URL: http//www.afssaps. sante.fr. Communiqué de presse du 4 juin 2002
27. Chazerain P. Trois cas de tendinopathie induite par une statine. Rev Med Interne 2000; 21 Suppl. 2: 268s
28. Jeppesen U, Gaist D, Smith T, et al. Statins and peripheral neuropathy. Eur J Clin Pharmacol 1999; 54: 835-8
29. Gaist D, Jeppesen D, Andersen M, et al. Statins and the risk of polyneuropathy: a case-control study. Neurology 2002; 58: 1333-7
30. Dujovne CA. Side-effects of statins: hepatitis versus 'transaminasitis': myositis versus 'CPKitis'. Am J Cardiol 2002; 89: 1411-3
31. Davidson MH. Safety profiles for the HMG-CoA reductase inhibitors. Drugs 2001; 61: 197-206
32. Tomlison B, Chan P, Lan W. How well tolerated are lipid-lowering drugs? Drugs Aging 2001; 18: 666-83
33. Chapman BA, Burt MJ, Chisholm RJ, et al. Dissolution of gallstones with simvastatin an HMG CoA reductase inhibitor. Dig Dis Sci 1998; 43: 349-53
34. Bruckert E, Giral P, Heshmati HM, et al. Men treated with hypolipidemic drugs complain more frequently of erectile dysfunction. J Clin Pharmacol Ther 1996; 21: 89-94
35. Harris ML, Bron AJ, Brown NA, et al. Oxford cholesterol study group. Absence of effect of simvastatin on the progression of lens opacities in a randomized. placebo-controlled study. Br J Ophtalmol 1995; 79: 996-1002
36. Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. London: BMJ Publishing, 1990: 14
37. Bjerre LM, Lelorier J. Do statins cause cancer?: a meta-analysis of large randomised clinicial trials. Am J Med 2001; 110: 716-23
38. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22
39. Sheperd J, Blaw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623-30
40. The LIPID Study Group. Long-term effectiveness and safety of pravastatin in 9 014 patients with coronary disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet 2002; 359: 1379-87